Online inquiry

IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1461MR)

This product GTTS-WQ1461MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD22 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001185099.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 933
UniProt ID P20273
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ1461MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9295MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMMU-132
GTTS-WQ10420MR IVTScrip™ mRNA-Anti-IL17A, LY2439821(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2439821
GTTS-WQ15604MR IVTScrip™ mRNA-Anti-SLC29A2, VAL-1221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA VAL-1221
GTTS-WQ9642MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ4864MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BTCT4465A
GTTS-WQ1988MR IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AGS-22CE
GTTS-WQ11982MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MM-005
GTTS-WQ13658MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW